🇺🇸 FDA
Pipeline program

BMN 190 recombinant human tripeptidyl peptidase-1 (rhTPP1)

190-203

Phase 2 mab completed

Quick answer

BMN 190 recombinant human tripeptidyl peptidase-1 (rhTPP1) for Jansky-Bielschowsky Disease is a Phase 2 program (mab) at BIOMARIN PHARMACEUTICAL INC with 1 ClinicalTrials.gov record(s).

Program details

Company
BIOMARIN PHARMACEUTICAL INC
Indication
Jansky-Bielschowsky Disease
Phase
Phase 2
Modality
mab
Status
completed

Clinical trials